Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Probosciseson Jan 19, 2023 7:42pm
496 Views
Post# 35234568

What The ONC/Y Insiders Have at Stake

What The ONC/Y Insiders Have at StakeThis is a collation of some earlier posts of mine showing the incentive the insiders have to achieve a good buyout price.

From SEDI (sedi.ca) we determined that management and the board of directors have the following shares and options in ONC/Y:

Management
1. Matt Coffey has 96,333 common shares and 1,354,631 options
2. Kirk Look has 45,028 common shares and 815,262 options
3. Thomas Heineman has 11,000 commonshares and 425,000 options
4. Andrew de Guttadauro has 10,315 common shares and 563,157 options
5. Allison Hagerman has 4,200 common shares and 507,683 options

Board of Directors
1. Wayne Pisano has 189,941 common shares and 83,420 options
2. Deborah Brown has 48,948 common shares and 65,263 options
3. Bernd Seizinger has 314,863 common shares and 65,263 options
4. Angela Holtham has 124,238 common shares and 65,263 options
5. James Parsons has 45,000 options
6. Jonathan Rigby has 45,000 options

The value of these insider held shares and options depends on the following:
a) number of fully diluted shares outstanding.  As of September 2022 the fully diluted shares were 64,388,508 which includes the options of the insiders. This represents 7.6% of the company.
b) buyout price. I used a buyout price of $2,000,000,000 USD although a higher price is possible.  Use whatever buyout price you are comfortable with and multiply my results by that factor. 

At the $2 billion USD buyout price and 64,388,508 total shares the insiders shares and options are worth the following in USD:


MANAGEMENT
Matt Coffey.                       $45,069,036
Kirk Look.                          $26,721,849
Thomas Heineman.           $13,542,789
Andrew de Guttadauro.     $17,812,868
Allison Hagerman.             $15,899,825

BOD
Wayne Pisano.                    $8,490,987
Deborah Brown.                  $3,547,559
Bernd Seizinger.                $11,807,262
Angela Holtham.                  $5,886,175
James Parsons.                   $1,397,765
Johnathan Rigby.                 $1,397,765

The weighted average excercise price of the outstanding options is around $2.57 USD per option (from the Q3 2022 Financial Report).  Therefore you can easily calculate the cost of exercising these options for each insider.  The cost is not much given a purchase price in the billions.

If you think a realistic  buyout price is more like $4 billion, $6 billion, or $8 billion, etc. then multiply my insider amounts by a factor of 2, 3, or 4, etc.  The insiders have a lot to gain and they will be highly motivated to maximize shareholder value. 


<< Previous
Bullboard Posts
Next >>